When Importers and Distributors Become Manufacturers Under MDR Article 16

1. Key takeaways

Under Article 16 of the MDR, an importer, distributor or other natural or legal person is deemed to be a manufacturer and assumes the manufacturer’s obligations under Article 10 where it: first, places devices already on the Union market on the market under its own name or trademark (with cases after relabelling or repackaging governed separately by the provision); second, changes the intended purpose of a device already on the market; or third, modifies a device in a way that could affect conformity. In addition, persons who repackage devices or translate the accompanying information must fulfil the corresponding obligations set out in the provision. The significance of Article 16 is that it is a role-change provision: the obligations of importers and distributors are verification and notification, while the obligations of a manufacturer span design, risk management, clinical evaluation, technical documentation, the quality management system, post-market surveillance and vigilance. Once the provision is triggered, the company must restructure from a trading entity into a compliance entity, including establishing a quality management system (Article 16(3)) and issuing its own EU declaration of conformity — borrowing the original manufacturer’s system does not suffice.

2. Legal basis

The role-change triggers and the obligations that follow are laid down in the following provisions.

3. Expert insights

Insight one: Article 16 is a role-change provision, and once triggered the order of magnitude of the obligations changes completely.

The obligations of importers and distributors are verification and notification (Articles 13 and 14), whereas the obligations of a manufacturer are the full set: design, risk, clinical evaluation, technical documentation, the quality management system, post-market surveillance and vigilance (Article 10). Once Article 16 is triggered, the company must rebuild itself from a trading entity into a compliance entity — including establishing a quality management system (Article 16(3)) and issuing its own EU declaration of conformity. This is not an incremental addition to an existing import or distribution licence; it is a change of regulatory identity, and the systems, personnel and records required grow accordingly.

Insight two: own-brand labelling (OEM / ODM arrangements) is the most common trigger.

Placing devices already on the Union market on the market under one’s own name or trademark falls directly within Article 16. Companies that apply their own brand often assume that because the original manufacturer already holds CE certification, applying a different label changes nothing. The legal consequence is the opposite: the own-brand supplier becomes a manufacturer and assumes the Article 10 obligations in its own name. Any commercial plan for an own-brand device range should therefore start with an Article 16 trigger assessment, not with the branding design, because the compliance cost of the manufacturer role must be priced into the business case before contracts are signed.

Insight three: repackaging and translation carry a notification obligation.

Under Article 16(2), a person that repackages devices and/or translates the accompanying information must, before placing the devices on the market, provide the manufacturer and the competent authority with samples or a mock-up of the repackaged or translated product, along with the other information required by the provision. Treating the translation of the instructions for use as a purely linguistic task means missing the notification to the competent authority, and that omission is precisely what market surveillance inspections look for. The workflow should therefore include a pre-market notification step with its own evidence file, completed for every product variant affected.

Insight four: a quality management system is mandatory in Article 16 scenarios.

Under Article 16(3), a person deemed to be a manufacturer under Article 16 must establish a quality management system complying with Article 10(9). This runs counter to the commercial intuition of borrowing the original manufacturer’s system — the system must be the company’s own. Access to the original manufacturer’s technical documentation is a supporting element, not a substitute: the company still needs its own declaration of conformity and its own post-market surveillance and vigilance processes at the manufacturer standard.

4. Practical recommendations

1. Run an Article 16 trigger assessment before the business starts: own-brand, changed intended purpose, modification, repackaging and translation, checked item by item.
2. Where a trigger applies, rebuild on the manufacturer basis: quality management system, access route to technical documentation, own EU declaration of conformity, and post-market surveillance and vigilance processes.
3. For repackaging and translation projects, establish a pre-market notification procedure providing the required information to the manufacturer and the competent authority.
4. The contract with the original manufacturer must state the right of access to technical documentation and the right to be informed of changes; otherwise the Article 10 obligations cannot be fulfilled.
5. Assess whether the commercial benefit covers the cost of the manufacturer’s obligations, and prefer business models that do not trigger the provision.

5. Verification checklist

Work through the following items before and after any Article 16 trigger is identified.

• □ The Article 16 trigger assessment is complete (own-brand / changed purpose / modification / repackaging / translation)
• □ In trigger scenarios, the quality management system of Article 10(9) is established
• □ The company’s own EU declaration of conformity has been issued
• □ A pre-market notification procedure for repackaging and translation is established (Article 16(2))
• □ The contract with the original manufacturer provides for access to technical documentation and notice of changes
• □ Post-market surveillance and vigilance processes are established to the manufacturer standard

Regulatory information verified as of 29 October 2026.

GRZAN advises importers and distributors in the European Union market on Article 16 role changes under the EU MDR, providing trigger assessments, quality management system guidance, EU Authorised Representative (AR) and PRRC services, EUDAMED registration support, and fee and budget planning for the manufacturer obligations that follow. Our team helps companies restructure from trading entities into compliance entities under Regulation (EU) 2017/745, with pre-market notification procedures for repackaging and translation projects and contract terms that secure access to technical documentation. For practical support with role changes, registration and budget matters, contact GRZAN at info@grzanglobal.com.